{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":324,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-09-14T18:21:24.973502+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"Cell Therapy Advances And Biotech Leadership With Nkarta's Paul Hastings","slug":"cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings","published_at":"2026-08-10T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19581874-cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19581874-cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at Nkarta, an allogeneic cell therapy developer, talks about building off-the-shelf CAR NK cell therapies for autoimmune disease. Paul is candid about problems with clinical trial infrastructure in the U.S., what it will take to fix trial access (biotechs should actively facilitate patient access to trials and work with community health center...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Paul Hastings, Founding CEO and Board Member at…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3026,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/cell-therapy-advances-and-biotech-leadership-with-nkarta-s-paul-hastings.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}